Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2251 to 2265 of 9102 results

  1. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development Reference number: GID-HST10062 Expected publication date:  17 March 2027

    Highly specialised technologies guidance
    In development

  2. Gender Incongruence Services for Children and Young People

    In development Reference number: GID-QS10193 Expected publication date:  18 February 2027

    Quality standard
    In development

  3. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

    Quality standard
    In development

  4. Vertebral body tethering for idiopathic scoliosis in children and young people

    Awaiting development Reference number: GID-HTG10657 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  5. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  04 September 2026

    Technology appraisal guidance
    In development

  6. Nemtabrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma without a 17p deletion or TP53 mutation

    Awaiting development Reference number: GID-TA12036 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 years

    Awaiting development Reference number: GID-TA12015 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  10. Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]

    In development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [ID6484]

    Awaiting development Reference number: GID-TA11632 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  11 November 2026

    Technology appraisal guidance
    In development

  13. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    Awaiting development Reference number: GID-TA11092 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Camizestrant as an add-on to a first-line CDK4/6 inhibitor for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]

    In development Reference number: GID-TA11995 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development